Breast And Ovarian Cancers
Genta's Decoy Program Suppresses Key Cancer Genes In Breast and Ovarian Cancer
Published in Cancer Weekly, November 6th, 2001
Genta Inc. has announced the publication of two scientific papers that show an important pipeline drug downregulated key cancer genes and exerted potent preclinical antitumor activity in breast and ovarian cancer. Using the Company's lead compound from its "Decoy Aptamer" program, the new papers derive from the laboratory of Dr. Yoon S. Cho-Chung from the U.S. National Cancer Institute. Genta holds an exclusive license to this technology.
"Decoy" technology involves using short DNA sequences to target proteins known as "transcription factors" that normally bind specific sequences in genomic DNA, thereby regulating downstream production of a protein. "Decoys" attach...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2001-11-06)
More Articles from Cancer Weekly
- Non-Hodgkin Lymphoma
Similar Efficacy In Stem Cell Graft Induction Regimens With Or Without Radiation - Skin Cancer
Tumor Vaccine Causes Regression, Reduces Metastasis In Incurable Melanoma - Breast Surgery
Acupuncture Is As Effective As Drugs For Pain, Nausea - Epidemiology
Researchers To Study Why Blacks Get, Die More From Cancer - Ovarian Cancer
Researchers Seek To Develop Test For Women's Deadliest Cancer - Risk Factors
Animal-Based Nutrients Linked With Higher Risk Of Stomach, Esophageal Cancers - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
